Discover the top 10 companies transforming the global autoinjectors market through advanced drug delivery technologies, patient-centric device design, and strategic partnerships. These industry leaders are accelerating innovation in self-administration solutions for chronic diseases, autoimmune disorders, diabetes, and emergency care applications. Growing demand for home-based healthcare, biologics, and connected drug delivery devices continues to fuel market expansion.
The global autoinjectors market, valued at USD 107.60 billion in 2025, stood at USD 127.30 billion in 2026 and is projected to advance at a resilient CAGR of 18.7% from 2026 to 2031, culminating in a forecasted valuation of USD 300.46 billion by the end of the period.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724
1. Becton, Dickinson and Company (BD)
BD is a major force in the autoinjectors ecosystem, leveraging its expertise in injectable drug delivery systems, prefillable syringes, and pharmaceutical manufacturing technologies. The company focuses on precision, patient safety, and scalable drug-device combination solutions. BD’s strong R&D capabilities and global manufacturing footprint strengthen its leadership position.
2. Ypsomed AG
Ypsomed is widely recognized for its innovative self-injection platforms and user-friendly autoinjector technologies. Its customizable systems support pharmaceutical companies developing biologics and specialty therapies. The company continues expanding manufacturing capabilities and strategic collaborations across therapeutic areas.
3. SHL Medical AG
SHL Medical specializes in advanced autoinjector and wearable injection solutions. Known for strong engineering capabilities, the company partners with pharmaceutical firms to develop high-performance delivery devices for biologics, GLP-1 therapies, and chronic disease treatments.
4. Amgen Inc.
Amgen plays a critical role in the autoinjectors market through biologic therapies delivered via its patient-friendly injection systems. Its widely used SureClick technology supports treatments for rheumatoid arthritis, osteoporosis, and inflammatory diseases, reinforcing its position in self-administered therapeutics.
5. Eli Lilly and Company
Eli Lilly continues to drive innovation in autoinjector-enabled therapies for diabetes, migraine, obesity, and autoimmune diseases. Its injection pens and self-administration platforms emphasize ease of use, treatment adherence, and improved patient outcomes.
6. AbbVie Inc.
AbbVie remains a leading player through its strong portfolio of biologics supported by autoinjector delivery systems. The company focuses on patient convenience and long-term disease management across immunology and specialty care applications.
7. Teva Pharmaceutical Industries Ltd.
Teva strengthens its market presence with autoinjector-enabled therapies targeting neurological disorders and chronic conditions. The company invests in improving self-injection experiences and expanding access to specialty drug delivery solutions.
8. Owen Mumford Ltd.
Owen Mumford is recognized for developing intuitive and customizable drug delivery devices. Its autoinjector platforms emphasize safety, ergonomic design, and compatibility with complex biologic formulations, making it a preferred partner for pharmaceutical companies.
9. Gerresheimer AG
Gerresheimer expands innovation in drug delivery through advanced autoinjector systems, primary packaging technologies, and integrated pharmaceutical device solutions. The company focuses on supporting next-generation injectable therapeutics.
10. Novo Nordisk A/S
Novo Nordisk is a major contributor to autoinjector market growth, particularly in diabetes and obesity care. The company combines therapeutic innovation with advanced injection technologies to enhance treatment adherence and home-based care delivery.
Market Outlook
The autoinjectors market is experiencing rapid growth due to increasing biologics adoption, rising prevalence of chronic diseases, and expanding demand for self-administration technologies. Innovations such as smart connected devices, reusable injectors, needle safety systems, and digital adherence monitoring are expected to shape the competitive landscape in the coming years.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724
